John De Kruif

John De Kruif is the SVP & Chief Technology Officer at Merus. John has over 20 years of experience in the biotech industry, with a focus on antibody research and development.

De Kruif began their career as a postdoc at Utrecht University in 1996. John then joined Ubisys as a senior scientist in 1998, before moving to Crucell in 2000 as Director of Antibody Discovery. John remained at Crucell for six years, before joining Merus in 2006.

De Kruif has played a key role in the development of several groundbreaking therapies, including the first human monoclonal antibody for the treatment of influenza. John is a world-renowned expert in antibody engineering, and their work has helped to shape the field as we know it today.

John De Kruif reports to Bill Lundberg, President, CEO, Principal Financial Officer, Executive Director. They work with L. Andres Sirulnik - EVP & Chief Medical Officer, Lex Bakker - SVP & Chief Development Officer, and Hui Liu - EVP, Chief Business Officer & Head of Merus U.S..